RxDoctor Payments Data

Lorena Alianza-Timog

Family · Hackettstown, NJNPI 1528496742

Payments from drug & device makers

$2,780in general payments, 2019–2025

Across 108 payments — averaging $25.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$560
  • Lilly USA, LLC$412
  • Medtronic$388
  • Novo Nordisk$330
  • Esperion Therapeutics, Inc.$131
  • Pharmacosmos Therapeutics Inc.$120
  • plus $839 from 18 others

What the payments were for

  • Food & beverage$2,780100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,780 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$53,168
Medicare patients
249
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide213$264,606
MounjaroTirzepatide213$234,168
OzempicSemaglutide124$167,430
JardianceEmpagliflozin104$93,606
RybelsusSemaglutide39$46,597
Fiasp FlextouchInsulin Aspart (Niacinamide)36$45,432
TradjentaLinagliptin66$43,796
Tresiba Flextouch U-100Insulin Degludec71$41,958
JanuviaSitagliptin Phosphate35$32,713
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog51$30,133
Humulin R U-500 KwikpenInsulin Regular, Human24$26,549
Bydureon BciseExenatide Microspheres22$22,807
FarxigaDapagliflozin Propanediol15$21,356
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/715$18,583
Lantus SolostarInsulin Glargine,hum.Rec.Anlog146$17,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$412$505,304442 claims
Novo NordiskOzempic, Rybelsus, Novolog$330$219,684174 claims
Boehringer IngelheimJardiance, Tradjenta$16$137,403170 claims
AstraZenecaFarxiga$15$21,35615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Hackettstown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →